Escalon Medical 10-K: $3M AXIS Sale Drives Profit, But Material Weakness Persists
ESMC sits 65% above its 52-week low of $0.1.
Summary
Escalon Medical Corp. reported fiscal 2026 net income of $4.0M, boosted by a $2.8M gain from selling its AXIS software business, but disclosed an unremediated material weakness in internal controls.
Key Events · Earnings and Guidance · ESMC
-
AXIS Software Sale Generates $2.8M
Company sold AXIS software assets to Optos for $3.0M, receiving $2.8M net proceeds and recognizing a $2.81M pre-tax gain during fiscal 2026.
-
Material Weakness Remains Unremediated
Material weakness in internal control over financial reporting related to inventory reserve calculations, first identified in fiscal 2023, continued to exist as of June 30, 2026. Disclosure controls and procedures were also concluded not effective.
-
Cash Position Strengthens to $3.07M
Cash on hand increased from $0.55M to $3.07M year-over-year, driven primarily by the AXIS sale proceeds. Working capital improved to $4.62M with a current ratio of 2.94 to 1.
-
Deferred Tax Valuation Allowance Released
Company released $1.14M of its deferred tax valuation allowance, recognizing a corresponding income tax benefit, after concluding it is more likely than not that a portion of deferred tax assets will be realized.
Analysis · ESMC · Industrial Applications And Services
Escalon Medical Corp. reported fiscal 2026 net income of $4.0M, driven almost entirely by the $2.8M net proceeds from selling its AXIS software business to Optos. The sale transformed the balance sheet — cash jumped from $0.55M to $3.07M and stockholders' equity more than tripled to $5.93M. However, the company disclosed that a material weakness in internal control over financial reporting, first identified in fiscal 2023, remains unremediated as of June 30, 2026. Management also concluded disclosure controls and procedures were not effective. For a micro-cap company with a market cap near $1.2M, the unremediated material weakness is a significant governance red flag that could undermine investor confidence in reported financials.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ESMC was trading at $0.17 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.10 to $0.46. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.